title: Identifying patients at risk for recurrent or advanced BCC.
abstract: Basal cell carcinoma (BCC) is a common skin cancer and its incidence is on the rise worldwide. Clinical presentation and histologic examination are used for diagnosis and to stratify BCCs as either low- or high-risk for recurrence or development of advanced disease. A number of surgical and nonsurgical options are available for BCC. BCC is most often managed with a surgical approach, but not all tumors and patients are suitable for surgery. Vismodegib is a recently approved first-in-class hedgehog pathway inhibitor that has expanded options for patients who have locally advanced or metastatic BCC.
authors.forename: Omid
authors.initials: O
authors.lastname: Hamid
authors.forename: Gary
authors.initials: G
authors.lastname: Goldenberg
mesh_terms: D000813:Anilides / Q000494:pharmacology / Q000627:therapeutic use*; D000970:Antineoplastic Agents / Q000494:pharmacology / Q000627:therapeutic use; D002280:Basal Cell Carcinoma / Q000175:diagnosis / Q000473:pathology / Q000628:therapy*; D017277:Drug Approval; D006801:Humans; D009362:Neoplasm Metastasis; D009364:Neoplasm Recurrence, Local; D011725:Pyridines / Q000494:pharmacology / Q000627:therapeutic use*; D012307:Risk Factors; D012878:Skin Neoplasms / Q000175:diagnosis / Q000473:pathology / Q000628:therapy*
chemical_list: D000813:Anilides; D000970:Antineoplastic Agents; C538724:HhAntag691; D011725:Pyridines